Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospital Universitari Vall d'Hebron Research Institute
About this trial
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Eligibility criteria
Qualifiers
Migraine diagnosis according to ICHD-III.
Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
Signature of informed consent.
Disqualifiers
Presence of headache different from migraine.
Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Trial design
Treatments tested in this trial
- CGRP antibody or gepant
Treatment groups
700 Participants
are divided into 1 treatment groupLocations
26Argentina
FLENI Buenos Aires Argentina
Chile
Pontificia Universidad Católica de Chile Santiago Chile
Colombia
Neuromedica Medellín Colombia
Croatia
Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno Rovinj Croatia
Sponsors and collaborators
Hospital Universitari Vall d'Hebron Research Institute
Lead sponsor
Source ClinicalTrials.gov